EntryPoint Capital’s Cabaletta Bio CABA Stock Holding History

EntryPoint Capital’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-8,641	Closed	-$147K	–	964
2024 Q1	$147K	Buy	+8,641	New	+$185K	0.13%	226

Other funds holding CABA

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

EntryPoint Capital's CABA Position: Q2 2024 in Review

EntryPoint Capital sold out of Cabaletta Bio (CABA) in Q2 2024, closing a stake of 8,641 shares — an estimated $147K sold.

EntryPoint Capital first reported a position in CABA in Q1 2024 and held it in 1 quarter. The position peaked at $147K in Q1 2024. 142 funds tracked by Wall St. Rank hold CABA as of Q2 2024.

EntryPoint Capital reported no remaining Cabaletta Bio position as of Q2 2024 after selling out during the quarter.
EntryPoint Capital sold 8,641 Cabaletta Bio shares in Q2 2024, an estimated $147K.
EntryPoint Capital first reported a position in Cabaletta Bio in Q1 2024 and held it in 1 quarter.
EntryPoint Capital's Cabaletta Bio position peaked at $147K in Q1 2024.
142 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.